

Amendments to the Claims

Please amend claims 13 and 14 as follows.

Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1-12. (Canceled)

13. (Currently Amended) A chimeric cytomegalovirus (CMV) virus which comprises:

(a) a polynucleotide sequence of a high-passage Towne genome from nucleotides 1 to 3799; (b) a polynucleotide sequence of a Toledo genome from nucleotides 15750 to 67568; (c) a polynucleotide sequence of a high-passage Towne genome from nucleotides 81647 to 170499; (d) a polynucleotide sequence of a Toledo genome from nucleotides 175069 to 203136; and (e) a polynucleotide sequence of a high passage Towne genome from nucleotides 205803 to S-term, wherein the high-passage Towne genome has been passaged at least 50 times and wherein the nucleotide number of the Towne and Toledo genomes is according to the numbering convention of the AD169 genome, EMBL accession number X17403.

14. (Previously Presented) A chimeric CMV virus which comprises: (a) a polynucleotide sequence of a high-passage Towne genome from nucleotides 1 to 3799; (b) a crossover region comprising SEQ ID NO.: 28; (c) a polynucleotide sequence of a Toledo genome from nucleotides 15750 to 67568; (d) a crossover region comprising SEQ ID NO.: 29; (e) a polynucleotide sequence of a high-passage Towne genome from nucleotides 81647 to 170499; (f) a crossover region comprising SEQ ID NO.: 30; (g) a polynucleotide sequence of a Toledo genome from nucleotides 175069 to 203136; (h) a crossover region comprising SEQ ID NO.: 31 and (i) a polynucleotide sequence of a high passage Towne genome from nucleotides 205803 to S-term, wherein the high-passage Towne genome has been passaged at least 50 times and wherein the nucleotide number of the Towne and Toledo genomes is according to the numbering convention of the AD169 genome, EMBL accession number X17403.

15-16. (Canceled)

17. (Previously Presented) An immunogenic composition comprising the chimeric virus of claim 13.

18. (Previously Presented) An immunogenic composition comprising the chimeric virus of claim 14.

19. (Withdrawn) A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human an immunological composition of claim 15 in an amount sufficient to stimulate an immune response in said human.

20. (Withdrawn) A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human an immunological composition of claim 16 in an amount sufficient to stimulate an immune response in said human.

21. (Withdrawn) A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human the immunological composition of claim 17 in an amount sufficient to stimulate an immune response in said human.

22. (Withdrawn) A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human an immunological composition of claim 18 in an amount sufficient to stimulate an immune response in said human.